Skip To Content

 

Insights

Blogs

 

Sharing perspectives leads to greater understanding and fuels innovation

Check out our latest blog posts:

August 17, 2022 · Public Policy & Regulatory Affairs Team
Read more...
August 11, 2022 · OWCA
This spring, Optum welcomed Jeannine Foster as our newest CEO Read more...
July 28, 2022 · Public Policy & Regulatory Affairs Team
Read more...
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more...
July 06, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more...
June 24, 2022 · Medicare Insights Team
On June 6, 2022, the Supreme Court ruled 7-2 in Gallardo v. Marstiller that Florida Medicaid was permitted reimbursement from a settlement involving a permanently disabled woman. The woman, Ms. Gallardo, was involved in a catastrophic injury when she was hit by a truck while exiting a school bus. Florida Medicaid previously paid $862,688.77 in medical expenses and was expected to continue paying for future medical expenses related to this incident. Read more...
June 23, 2022 · Public Policy & Regulatory Affairs Team
Read more...
May 31, 2022 · Public Policy & Regulatory Affairs Team
Read more...
<< Previous      Next >>
Page 2 of 19